Project Details
Description
An Expanded Access Program for Elotuzumab in Combination with Lenalidomide plus Dexamethasone in Patients with Relapsed or Refractory Multiple Myeloma
| Status | Finished |
|---|---|
| Effective start/end date | 5/1/15 → 12/31/16 |
Funding
- BRISTOL-MYERS SQUIBB COMPANY
Fingerprint
Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.